autism-vaccine link?

Given that people who buy into the autism-vaccine link probably don't entirely trust the medical profession, quite a lot.
okay, but how doctors are influenced by drug reps to use medications is not the same as the fact that measles is a real threat (cicken pox I am not so sure) but measles is a real threat and it does harm to people who have an infection.

So the cost benefit ratio of mass vaccination against measles is very different it is something more like:
- cost of (vaccination side effects)/cost of (measles infection)
in that there is a risk of vaccination (autism not having been demonstrated to be one of them) like Reyes syndrome and other febrile disorders, but there are also serious consequences of measles infection so then the cost benefit ration becomes more like:
-(number of cases of negative reactions to vaccination)(cost of vaccination side efects)/(number of cases of measles infections)(cost of measles infection)

and so while certainly the rate of chicken pox vaccination and the cost vs. risk ratios are likely to be not as beneficial, the epidemiology of measles and the effects of vacinations are not going to be subject to marketing.

There is hard data here:
-costs of vaccination vs. -costs of measles

These are not open to marketing and influence of marketsing, they are based upon population and demographics and data collection.


Yes. There's a good article on shingles here, and one on varicella here.

So what effects does the vaccine have on an elderly person who is having an outbreal of the shingles for the first time when they are in thier seventies?
 
The case of the specialist who was selected by the pharmaceutical company to speak at a CME event but was totally unaware of that fact as were the medical practitionere attending the event.
The case of the medical practitioner who was selected by the pharmaceutical company and actually coached in how to present his talk at a CME event. He had what most would consider an unduly optimistic view on the use of Duromine in the treatment of obesity and mentioned the brand name at least six times during his talk. These facts were hidden form the audience
The case of the four CME events on analgesia, sponsored by the manufacturer of Tramal who was able to have a session on migraines included in the seminar and was able to ask for and recieve the attitude of the various speakers towards their drug.

When I said that they were unsuccessful at influencing the actual presentation, I meant that the content of the presentations was not changed. Sorry if that wasn't clear.

Fine, but it is a problem, isn't it, that a speaker is selected who has a view that is slanted towards the pharmaceutical companies products. The use of the second physician was a good move though, yes.

The listeners may think the individual's opinion is more representative of the consensus among experts than it is. But I would guess that the main benefit is from name recognition/recall.

But it would be a problem for you, wouldn't it, if the increased sales of their product was not in line with what the evidence says is best practice and if this result was achieved by their sponsorship of CME events where they actually paid for the right to select speakers with views favourable to their product? What is the chance, do you think, that the PCs outcome would coincide with best practise?

But wouldn't it be against the odds that a pharmaceutical companies push to sell it's products by their sponsorship of CME events would coincide with what would be considered best practise. They would be slanting the actual practise towards the use of their products, wouldn't they?

On this point, I'm going to go with whether there is evidence that says it isn't best. I'll explain why with your anti-hypertensives example.

Yes, and when "marketing" doesn't coincide with "education", who wins the day? Here is an example form a year or so ago:
The evidence apparently suggests that the older much cheaper anti-hypertensive drugs are just as good, if not better, than the newer much dearer alternatives, yet medical practitioners are prescribing the newer much dearer drugs much more frequently than the older cheaper drugs.
I suppose that could have been the result of "brand recognition". The different pharmaceutical companies promoting the recognition of their particular brand of the new anti-hypertensive drugs with the result that all of them are effectively promoting the use of these dearer but no more effective drugs amongst the medical profession.

This is a good example. There are several classes of anti-hypertensives and the bulk of them are still under patent. And while there may be generic versions available for the drugs that represent the initial entry into the class, the later entries mostly do represent significant (if minor) improvements in that class. The evidence suggests that newer drugs are safer and more effective (and in some cases, more effective means compliance is more complete due to convenient dosing (one-a-day vs. four times a day, for example) and reduced side-effects). However, we also know that safety and efficacy tends to look better in the setting of Phase II and III trials than it does in effectiveness trials and real world use. Evidence-based guidelines tend to take that in to account and give more weight to the use of older, more established drugs (with the expectation that as newer drugs are used generally and studied more thoroughly, their safety and effectiveness profiles will begin to match those of the older drugs). And they also tend to take cost in to account, even though it may not be relevant at an individual level. Evidence-based guidelines help to answer those questions for which evidence is available, but patient characteristics play a much larger role in the variation of outcomes than quality of care. This means that even strictly following the guidelines will lead to variation in the use anti-hypertensives.

And there really is very little to use to choose between them. If you're lucky, co-morbidities will guide the choices. But even if you narrow it down to one or two classes, you are still faced with indecision. If you divide your choices into older drugs for which generic versions and long-term safety data are available vs. newer drugs that appear to be much safer, it's still a matter of attempting to weigh various unknowns. And in many cases, not only does the evidence not show that a particular choice isn't the best, it may even suggest that it is.

It isn't so much that one particular brand of anti-hypertensives is being chosen over others, but rather, as you pointed out, that brand names are being chosen over generics. I suspect that represents greater awareness of (the appearance of) improved safety and convenience in the newer drugs, as drug reps (over) emphasize these characteristics.

I will admit that I don't like this. I won't participate in CME activities involving pharmaceutical companies. I don't accept information from drug reps, or from the plethora of journals and proceedings of such-and-such-conference that I receive free in the mail, as most of them are heavily disguised products of pharmaceutical companies. The research may be legitimate, but the selection of which research to present must be assumed to be biased. My own personal practices are stricter than those in the guidelines that I referenced earlier. Yet I cannot prove to my colleagues that do have dealings with drug reps, that in any individual case my choice of drug to recommend is any better than theirs. Especially since I often recommend the same brand-name drugs, on the basis of evidence and in the absence of that influence, as others are using. The argument is more philosophical than empirical.

Linda
 
okay, but how doctors are influenced by drug reps to use medications is not the same as the fact that measles is a real threat (cicken pox I am not so sure) but measles is a real threat and it does harm to people who have an infection.

So the cost benefit ratio of mass vaccination against measles is very different it is something more like:
- cost of (vaccination side effects)/cost of (measles infection)
in that there is a risk of vaccination (autism not having been demonstrated to be one of them) like Reyes syndrome and other febrile disorders, but there are also serious consequences of measles infection so then the cost benefit ration becomes more like:
-(number of cases of negative reactions to vaccination)(cost of vaccination side efects)/(number of cases of measles infections)(cost of measles infection)

and so while certainly the rate of chicken pox vaccination and the cost vs. risk ratios are likely to be not as beneficial, the epidemiology of measles and the effects of vacinations are not going to be subject to marketing.

There is hard data here:
-costs of vaccination vs. -costs of measles

These are not open to marketing and influence of marketsing, they are based upon population and demographics and data collection.

You're preaching to the converted here. MMR protects against three diseases, one of which is moderately dangerous (measles) and costs $17.60/dose. Seems like a no-brainer to me.

Varicella vaccine protects against 1 disease (or 2 if you include a later outbreak of Zoster) which is unlikely to be dangerous and costs $59.15/dose.

BTW, does anyone know how long the varicella vaccine has been around? I was under the impression a vaccine for chickenpox had been developed in the 1970's, but perhaps I'm mistaken.

So what effects does the vaccine have on an elderly person who is having an outbreal of the shingles for the first time when they are in thier seventies?

I'm not entirely sure what you're asking. Do you mean if the vaccine was used on her, or what the effects are of the vaccine being used on other people around her?

There is a vaccine for shingles which is now being recommended for all adults over the age of 60 in the US. It's basically a stronger version of the varicella vaccine. IIRC, it reduces the chances of having an outbreak of Zoster by ~50% and costs ~$140/dose.

I think the effect of vaccinating children today is unlikely to have much impact on 70 year-olds, since their chances of being exposed to wild-type varicella (thus having their immunity boosted) would be low even if routine childhood varicella vaccination was not implemented.

That's is unless grandma looks after the kids while they're off school with chickenpox. (I had chickenpox while on holiday at my grandparent's house.)
 
That's is unless grandma looks after the kids while they're off school with chickenpox. (I had chickenpox while on holiday at my grandparent's house.)


When I was a little bitty boy, just up off the floor,
We used to go down to Grandma's house, every month end or so.
I caught the pox, I felt real bad, the fever went to my head;
The next thing I knew I woke up in the morning in the middle of the old feather bed.

After supper, we sat around the fire, I tried to spit and chew;
My old grandma called the neighbours out, and said "Would ya like a view?"
"Get all your kids, and bring 'em round, it'll cost two bucks a head,
But I guarantee by the next full moon, they'll be poxed and in their beds."

My face felt nine feet high and six feet wide, and rough as a fresh-plucked chick,
I never knew that delerium was so bad when you're sick.
I hurled my guts, and scratched my skin, and the pus oozed from my head,
I didn't get much sleep but I sure got bugs from my Grandma's feather bed.

Now I love my Ma, I love my Pa, my Granny and Grandpa too,
But I wish they'd listened to that wise old bird, who tried to vax for flu.
He told us there were jabs for me, that would keep the pox away,
But they said, "No son, he's a doctor, see, a shill from the FDA."

"You can't trust him, you never know if he's got some shares you see;
Or if he's gone and got ten bucks from the guys at the CDC."
So they let me be, and now the pox has filled me with dismay,
but I console myself, cos I know they'll all get shingles some day.

But I'm six feet down - I've gone and died, under the ground I dwell;
For the damn chick pox destroyed my brain (though some folk couldn't tell);
My old grandma, she's wiser now, and many's the tears she's shed;
If they'd only thought to keep those Staph out of Grandma's feather bed.
 
Last edited:
I already thought you were a nice person. I don't think you're necessarily wrong. I think you're overconfident regarding this particular issue, just as I thing Linda is overconfident in the effectiveness of self-regulation of medical professionals.
Well I happen to think it is you who is overconfident. I am 'just right'-confident based on education and experience and I believe Linda is as well. While you are 'over'-confident because you have drawn conclusions believing something those who have more education and experience are telling you is wrong, and, you have made little effort to find out if that is true. Rather, you ignored the examples I gave (and repeated since you first ignored them) and you continue to ignore those examples.

I have yet to hear your response defending your conclusions which I provided those examples where your lack of education and experience led you to incorrect ends. You have not said anything about what you know that makes what I posted invalid as far as your conclusions.

In other words, rather than defend your conclusions after being shown what you missed, you just went on your merry way believing you know what it is you are talking about, when in these two cases you made blundering errors.
 
The varicella vaccine has been in use in the US only since about the early nineties. I didn't look up the specifics. I'm going by how old my son was when it was approved for use.

And the vaccine protects against primary varicella as well as secondary bacterial invasive group A strep (IE flesh eating bacteria) that can infect a chicken pox lesion.
 
Last edited:
Forgot to mention, Ivor doesn't think spending $120/ for 2 doses of varicella vaccine is worth the cost. Of course that's because he doesn't have any kids so he hates the idea of spending national health insurance dollars to save other people's kids' lives unless he feels he can get his money's worth. :rolleyes:
 
Last edited:
<snip>

I have yet to hear your response defending your conclusions which I provided those examples where your lack of education and experience led you to incorrect ends. You have not said anything about what you know that makes what I posted invalid as far as your conclusions.

In other words, rather than defend your conclusions after being shown what you missed, you just went on your merry way believing you know what it is you are talking about, when in these two cases you made blundering errors.

I do try to answer questions people put to me, but if I have missed any could you either post them again, or point me to the post(s) with the questions you want me to answer?
 
Twice, Ivor I pointed out your errors. And twice you ignored them and acted as if you made none. Now you say post them again? I don't think so.
 
Forgot to mention, Ivor doesn't think spending $120/ for 2 doses of varicella vaccine is worth the cost. Of course that's because he doesn't have any kids so he hates the idea of spending national health insurance dollars to save other people's kids' lives unless he feels he can get his money's worth. :rolleyes:

I think it's bizarre that a product (varicella vaccine) which provides such little benefit is twice as expensive as another (MMR vaccine) which provides 30-100 times the benefit.

Is the varicella vaccine particularly difficult to manufacture compared to MMR?
 
You think that Ivor, but it is a poorly informed opinion.

And here is your third error. All new drugs are overpriced for several reasons. One, because they can. Two, because the drug companies feel justified recouping R&D. Three, because the patents have not expired.

You cannot compare MMR pricing, a drug which has been on the market for 40 years with varicella vaccine, a drug less than a third as long on the market.
 
Last edited:
You think that Ivor, but it is a poorly informed opinion.

<snip>

Ok. I give up. As I said many pages ago, no matter how much I read, you will always consider my opinion poorly informed compared to your own. (There's a word to describe a person with that type of attitude...:))

I've had a look back at the posts where you pointed out errors I have made, and found in each case you have asserted I thought or said something I have not, then argued against that.
 
Sorry for the delay - the footy season has started.
I guess I'm supposed to know what that means..


I suppose you must be having a little joke at my expense :D
But, just in case you are serious, I was referring to the start of the Australian Football League 2008 season.

These are examples of things which serve to favour my satisfaction with the process:

Surveys such as the one referenced by Ivor earlier that show a very high commitment to professionalism and that behaviour follows from that attitude.*

Guidelines that are increasingly restrictive.

Increasing recognition of the role of influence through research and education.

Presentation of published research in a manner that encourages concern, rather than complacency.

Top-down dissemination of knowledge and attitudes from professional organizations, academic medical centres, regulatory bodies, etc.

Research that consistently shows that physicians will change behaviour in response to evidence.

Examples of the results of influence which cannot be demonstrated to not be in the patient's best interest (more on that in the next post).


I am happy to hear that this, in your opinion, is the case in the US.
I hope that also applies to Australia.

Examples of things which defeat the process:

Resistance to the recognition of personal susceptibility to influence among physicians.

Huge disparity in resources dedicated to the task between pharmaceutical companies (dedicated to influence) and healthcare workers (dedicated to resisting influence).

In the US, lack of commitment on the part of legislators to back-up efforts made by professional organizations.


I am constantly amazed by medical professionals who refuse to accept that they are susceptible to influence.
And, according to Medicines Australia, every year in Australia pharmaceutical companies spend $31 million on educational events for doctors (including $16 million for food and accomodation.)
http://www.medicinesaustralia.com.au/pages/page136.asp

Overall, I am reasonably confident that the direction we continue to move when it comes to knowledge/attitude/behaviour will ensure that this does not develop into a demonstrable problem.


I hope that is the case both in the US and here.

But how would that [the levy system] change what happens now? Wouldn't there still be incentive for them to be a bit sneaky about influencing healthcare workers? Unless you are talking about forbidding advertising when it comes to pharmaceuticals - just the sort of anti-capitalist, anti-innovation propaganda I'd expect from those commie-universal-health-care proponents.


Now you must be at least half joking. "Commie" no, but universal health care? I know you couldn't be against that.
As for advertising, capitalism be damned! Presently in Australia pharmaceutical companies are not allowed direct-to-consumer advertising of prescribed medications. That is not he case in the US, I believe. I hope that never eventuates here. Of course the pharmaceutical companies partially circumvent this with "community service" anouncements where they highlight a particular "disease" like obesity and then ask you to discus the treatent that is "now available" with your doctor. And the doctors are usually sent a flier warning them of the inrush of patients responding to their "community announcement" and supplying the answer to the question their patients will inevitably ask - the NAME of that new treatment for obesity that is "now available".

Regards,
BillyJoe
 
When I said that they were unsuccessful at influencing the actual presentation, I meant that the content of the presentations was not changed. Sorry if that wasn't clear.


But, if they can influence the choice of speakers and, if they can influence the topics being discussed, how is that not influencing the actual presentation? The actual presentation would have been different without their influence wouldn't it?

The listeners may think the individual's opinion is more representative of the consensus among experts than it is. But I would guess that the main benefit is from name recognition/recall.


Well, okay, perhaps a bit of both.

This is a good example. There are several classes of anti-hypertensives and the bulk of them are still under patent. And while there may be generic versions available for the drugs that represent the initial entry into the class, the later entries mostly do represent significant (if minor) improvements in that class.


I think it was more to do with the entry of new classes of hypertensive medications into the field. They tend to be about 4X dearer but, reportedly, no more effective than the earlier classes of hypertensive medications

The evidence suggests that newer drugs are safer and more effective (and in some cases, more effective means compliance is more complete due to convenient dosing (one-a-day vs. four times a day, for example) and reduced side-effects).


That would certainly be an argument in their favour. I can't imagine anyone wanting to take medication more than once a day if at all possible. Still, the diuretic class of antihypertensive medications are a once a day treatment and this is one of the oldest and cheapest classes of hyertensive drugs on the market. If side-effects were an issue and, if they were just as effective as the newer classes, they should be considered first line and a change made to the newer, more expensive, classes of drugs if side-effects proved to be a problem in any particular patient.

However, we also know that safety and efficacy tends to look better in the setting of Phase II and III trials than it does in effectiveness trials and real world use. Evidence-based guidelines tend to take that in to account and give more weight to the use of older, more established drugs (with the expectation that as newer drugs are used generally and studied more thoroughly, their safety and effectiveness profiles will begin to match those of the older drugs).


Yes, Vioxx comes to mind here.
The miracle drug for arthritis becomes the death drug for heart patients.
(I know that is probably an exaggeration.)

And they also tend to take cost in to account, even though it may not be relevant at an individual level


In Australia the cost for the patient is the same regardless of the actual cost of the drug but, with the entry of the more expensive classes of drugs, the pharmaceutucal benefits scheme threatens to go broke and the whole system is saved by racking up the patient contribution.

And there really is very little to use to choose between them. If you're lucky, co-morbidities will guide the choices. But even if you narrow it down to one or two classes, you are still faced with indecision. If you divide your choices into older drugs for which generic versions and long-term safety data are available vs. newer drugs that appear to be much safer, it's still a matter of attempting to weigh various unknowns. And in many cases, not only does the evidence not show that a particular choice isn't the best, it may even suggest that it is.


Sorry, I'm having trouble parsing that last sentence :o but you are saying that doctors need a range of choices to match a range of patients with different assosciated illnesses. That's fine, but the advertising push for the newer more expensive classes of drugs would still tend to skew the choice in their favour even when (if?)the older cheaper drugs would work just as well.

It isn't so much that one particular brand of anti-hypertensives is being chosen over others, but rather, as you pointed out, that brand names are being chosen over generics. I suspect that represents greater awareness of (the appearance of) improved safety and convenience in the newer drugs, as drug reps (over) emphasize these characteristics.


Agreed though, again, I was distinguishing more between the newer and older classes of drugs, rather than just between the brand name and generic drugs.

I will admit that I don't like this. I won't participate in CME activities involving pharmaceutical companies. I don't accept information from drug reps, or from the plethora of journals and proceedings of such-and-such-conference that I receive free in the mail, as most of them are heavily disguised products of pharmaceutical companies. The research may be legitimate, but the selection of which research to present must be assumed to be biased. My own personal practices are stricter than those in the guidelines that I referenced earlier.


Well, that sounds to me like the right sort of attitude to have towards drug companies and drug reps. It sounds like you are one of those rare few (or may I hope that you will argue one amongst many :) ) doctors who strive to keep the pharamceutical companies at a good safe distance.

Yet I cannot prove to my colleagues that do have dealings with drug reps, that in any individual case my choice of drug to recommend is any better than theirs. Especially since I often recommend the same brand-name drugs, on the basis of evidence and in the absence of that influence, as others are using. The argument is more philosophical than empirical.


Well, for what it is worth, I think the philosophical position is important.

regards,
BillyJoe
 
Ok. I give up. As I said many pages ago, no matter how much I read, you will always consider my opinion poorly informed compared to your own. (There's a word to describe a person with that type of attitude...:))

I've had a look back at the posts where you pointed out errors I have made, and found in each case you have asserted I thought or said something I have not, then argued against that.
This is BS, Ivor. Your claims that where I pointed out errors they were straw men is BS as well. Where I pointed out your errors, you still didn't get it even when they were specifically pointed out to you. Here is an example of one of the issues you believe you addressed that you did not!

Post 282: Your argument that health care professionals were biased drifted from, 'the bias affects the entire health care community that provides oversight for ACIP and similar recommendations' to, 'the ACIP was affected by some bias'.

I agreed there would be some small effect of bias within the ACIP, but you never provided convincing evidence that bias affected all the oversight. When confronted with this problem in your view of the situation you answered the bias was in the ACIP itself thus ignoring the fact you had not demonstrated bias affected all the oversight.

Round and round the mulberry bush,
skeptigirl chased the weasel.....

We know who is on the ACIP Ivor. We are talking about the entire medical community of providers and researchers who have been surprisingly :rolleyes: silent in noticing much is wrong with the ACIP conclusions.
Take off your brain block, Ivor. It gets annoying at this point in your arguments.

Address your claim that the entire medical community is so homogeneously biased they cannot provide sufficient oversight of the ACIP and similar recommendations but someone such as yourself who lacks medical education and experience can see through all that bias and have a superior opinion on a complex issue such as vaccine recommendations simply by doing a little part time reading.

Anyone reading the pros and cons of these issues can certainly form an opinion. And they can certainly make valid comments on the matter. Where the problems come in is, for example, when you were confronted with the fact you first claimed the entire medical community was too biased to provide oversight, you tried to weasel out and claim the ACIP was biased. In doing so you never addressed your initial claim that there was no oversight. Oversight was the issue, Ivor, not the committee's bias.


And I'll repeat my examples over and over as long as you keep posting this childish reply that failing to convince anyone means they are ignoring your points because they discount your expertise. I discount your expertise because you demonstrate you lack a full command of the issues here Ivor, not because you don't have MD after your name.
 
Last edited:
I am constantly amazed by medical professionals who refuse to accept that they are susceptible to influence.

Really? I don't think selection and training manages to make us that much different from everyone else. Not past the point where at least some still have a few foibles, anyway.

Now you must be at least half joking. "Commie" no, but universal health care? I know you couldn't be against that.

If we were in a universal health care thread, particular posters would be criticizing our suggestions as stifling to innovation. 'Tis a fine line I have to walk.

Linda
 
But, if they can influence the choice of speakers and, if they can influence the topics being discussed, how is that not influencing the actual presentation? The actual presentation would have been different without their influence wouldn't it?

I agree. It's just that the point I was making was specific to what the speakers actually said.

I think it was more to do with the entry of new classes of hypertensive medications into the field. They tend to be about 4X dearer but, reportedly, no more effective than the earlier classes of hypertensive medications

Ah. No. It really is to our benefit to have these different classes of drugs. More-so because they are effective in other conditions. But they do represent necessary choices for the treatment of hypertension as well.

That would certainly be an argument in their favour. I can't imagine anyone wanting to take medication more than once a day if at all possible. Still, the diuretic class of antihypertensive medications are a once a day treatment and this is one of the oldest and cheapest classes of hyertensive drugs on the market. If side-effects were an issue and, if they were just as effective as the newer classes, they should be considered first line and a change made to the newer, more expensive, classes of drugs if side-effects proved to be a problem in any particular patient.

Assuming it didn't kill them, of course. The concerns are serious and shouldn't be dismissed too lightly.

Well, that sounds to me like the right sort of attitude to have towards drug companies and drug reps. It sounds like you are one of those rare few (or may I hope that you will argue one amongst many :) ) doctors who strive to keep the pharamceutical companies at a good safe distance.

I'm not so uncommon as you make out. In particular, I am not unusual when it comes to those physicians who influence other physicians as teachers and as members of professional organizations.

Well, for what it is worth, I think the philosophical position is important.

regards,
BillyJoe

As do I.

Linda
 
Linda,

Thanks for you perspective on this issue.

Australia actually does have a medical scheme that covers all its citizens more or less equally. You can opt into the private system but there is often no so much of an advantage in doing so. All emergencies get treated as emergencies and, generally the public system works best in these situations. You might, however, wait a while for a total hip replacement and there is a bit of a queue for coronary bypass surgery. It remains to be seen if this will be reversed after the demise of the Howard government recently.

As for the naive view about lack of influence from pharmaceutical industry, perhaps medical training is lacking somewhere. Perhaps a little more psycology, a bit more science, and a course or two in critical thinking. A drug rep visits the average medico perhaps twice every week spending perhaps 10-15 minutes giving him the low down on his latest drug together with a few goodies inscribed with the company's new brand name drug, takes him out to free lunches every month or so, and invites him to weekend seminars where he is lavished with five star accommodation and food. But he believes he is not being influenced because he is so clever because he got into medical school after all. Even if the influence ultimately does not have much of an adverse affect on patient management, it is still an unhealthy relationship with at least the potential for harm.

It is good to know that at least there are some many :) medicos who are trying to correct that naive view amongst their peers and their students and who strive to promote a more independent approach in relation to continuing medical education.

regards,
BillyJoe
 

ISF - Join now!

Every member here is approved by hand. No bots, no spam, just people who care about evidence and honest debate.

Membership is free!

Create your free account

Back
Top Bottom